268 related articles for article (PubMed ID: 23861993)
1. Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.
Ramirez-Ramirez V; Macias-Islas MA; Ortiz GG; Pacheco-Moises F; Torres-Sanchez ED; Sorto-Gomez TE; Cruz-Ramos JA; Orozco-Aviña G; Celis de la Rosa AJ
Oxid Med Cell Longev; 2013; 2013():709493. PubMed ID: 23861993
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis.
Sánchez-López AL; Ortiz GG; Pacheco-Moises FP; Mireles-Ramírez MA; Bitzer-Quintero OK; Delgado-Lara DLC; Ramírez-Jirano LJ; Velázquez-Brizuela IE
Arch Med Res; 2018 Aug; 49(6):391-398. PubMed ID: 30595364
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the effect of adding Fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial.
Zandi-Esfahan S; Fazeli M; Shaygannejad V; Hasheminia J; Badihian S; Aghayerashti M; Maghzi H
Clin Neurol Neurosurg; 2017 Dec; 163():173-178. PubMed ID: 29126030
[TBL] [Abstract][Full Text] [Related]
5. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
Trenova AG; Slavov GS; Manova MG; Kostadinova II
Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
[TBL] [Abstract][Full Text] [Related]
6. T-cell interleukin-6 receptor binding in interferon-beta-1b-treated multiple sclerosis patients.
Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
Eur J Neurol; 2000 Nov; 7(6):647-53. PubMed ID: 11136350
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory and therapeutic effects of Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients.
Rezapour-Firouzi S; Arefhosseini SR; Mehdi F; Mehrangiz EM; Baradaran B; Sadeghihokmabad E; Mostafaei S; Fazljou SM; Torbati MA; Sanaie S; Zamani F
Complement Ther Med; 2013 Oct; 21(5):473-80. PubMed ID: 24050582
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Serological Biomarkers of Treatment's Response in Multiple Sclerosis Patients Treated Continuously with Interferonβ-1b for More than a Decade.
Bărcuţean LI; Romaniuc A; Maier S; Bajko Z; Moţăţăianu A; Adina H; Simu I; Andone S; Bălaşa R
CNS Neurol Disord Drug Targets; 2018; 17(10):780-792. PubMed ID: 30221605
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
10. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
[TBL] [Abstract][Full Text] [Related]
11. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
[TBL] [Abstract][Full Text] [Related]
12. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
[TBL] [Abstract][Full Text] [Related]
13. The effects of fish oil supplementation on markers of inflammation in chronic kidney disease patients.
Deike E; Bowden RG; Moreillon JJ; Griggs JO; Wilson RL; Cooke M; Shelmadine BD; Beaujean AA
J Ren Nutr; 2012 Nov; 22(6):572-7. PubMed ID: 22285316
[TBL] [Abstract][Full Text] [Related]
14. Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.
Kallaur AP; Reiche EMV; Oliveira SR; Simão ANC; Pereira WLCJ; Alfieri DF; Flauzino T; Proença CM; Lozovoy MAB; Kaimen-Maciel DR; Maes M
Mol Neurobiol; 2017 Jan; 54(1):31-44. PubMed ID: 26732588
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection.
Nakatsuji Y; Nakano M; Moriya M; Kishigami H; Tatsumi C; Tada S; Sadahiro S; Naka T; Mitani K; Funauchi M; Azuma T; Watanabe S; Kinoshita M; Kajiyama K; Yuasa Y; Kaido M; Takahashi MP; Naba I; Hazama T; Sakoda S;
Cytokine; 2006 Oct; 36(1-2):69-74. PubMed ID: 17161613
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Control Trial Study to Determine the Effect of Melatonin on Serum Levels of IL-1β and TNF-α in Patients with Multiple Sclerosis.
Yosefifard M; Vaezi G; Malekirad AA; Faraji F; Hojati V
Iran J Allergy Asthma Immunol; 2019 Nov; 18(6):649-654. PubMed ID: 32245308
[TBL] [Abstract][Full Text] [Related]
17. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
[TBL] [Abstract][Full Text] [Related]
18. Effects of a Low Dose of Fish Oil on Inflammatory Markers of Brazilian HIV-Infected Adults on Antiretroviral Therapy: A Randomized, Parallel, Placebo-Controlled Trial.
Oliveira JM; Rondó PH; Lima LR; Fortuna ES; Yudkin JS
Nutrients; 2015 Aug; 7(8):6520-8. PubMed ID: 26251920
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.
Ozenci V; Kouwenhoven M; Huang YM; Kivisäkk P; Link H
Clin Exp Immunol; 2000 Apr; 120(1):147-53. PubMed ID: 10759776
[TBL] [Abstract][Full Text] [Related]
20. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
van Boxel-Dezaire AH; van Trigt-Hoff SC; Killestein J; Schrijver HM; van Houwelingen JC; Polman CH; Nagelkerken L
Ann Neurol; 2000 Sep; 48(3):313-22. PubMed ID: 10976637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
